Quantum BioPharma Ltd. Seeks Shareholder Approval for $600K Private Placement

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has announced its intention to seek shareholder approval for a non-brokered private placement of class A multiple voting shares (MVS) aiming to raise up to $600,000. This strategic move is set to be discussed at the company's annual general and special meeting scheduled for September 26, 2025. The proceeds from this offering are earmarked for general working capital, underscoring the company's commitment to sustaining its operations and furthering its research and development initiatives.

The private placement is expected to be fully subscribed by existing MVS holders, with the closing anticipated around the meeting date, pending approval. In compliance with Canadian securities laws, all securities issued will be subject to a four-month-plus-one-day hold period. This financial maneuver is a critical step for Quantum BioPharma as it continues to focus on developing innovative biotech solutions for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders.

Quantum BioPharma's portfolio includes its lead compound, Lucid-MS, a patented new chemical entity with potential applications in preventing and reversing myelin degradation, a key factor in multiple sclerosis. The company's strategic investments and partnerships, such as its 20.11% stake in Unbuzzd Wellness Inc. and the associated royalty agreements, further illustrate its diversified approach to growth and innovation in the biopharmaceutical sector.

For more details on Quantum BioPharma's latest developments, interested parties can visit https://ibn.fm/QNTM. This private placement represents a pivotal moment for Quantum BioPharma as it seeks to bolster its financial resources and continue its mission of addressing some of the most challenging health issues through cutting-edge science and technology.